IL-3 Signaling Reprograms Microglia to Clear Alzheimer's Aggregates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of glial cell interactions in Alzheimer's disease, particularly regarding β-amyloid and neurofibrillary tau accumulation and clearance, is limited, and existing therapies are ineffective in addressing the underlying pathological processes.
Innovation Solution
Administration of an Interleukin 3 Receptor (IL3R) agonist, such as an IL3 peptide or nucleic acid encoding an IL3 peptide, to modulate IL-3 signaling in the brain, promoting microglial reprogramming and clearance of β-amyloid and tau aggregates.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing therapies are used to treat Alzheimer's disease, then treatment is provided, but they are ineffective in addressing the underlying pathological processes of β-amyloid and tau accumulation
Solution Approach 1:
The patent uses IL-3 as an intermediary substance to mediate between astrocytes and microglia. Astrocytes produce IL-3, which acts as a signaling molecule to reprogram microglia, enabling them to effectively clear β-amyloid and tau aggregates. This intermediary approach addresses the failure of existing therapies by introducing a new molecular mediator that restores proper glial cell communication and function.
Solution Approach 2:
The patent changes the functional state of microglia through IL-3 signaling, transforming them from an ineffective state to an activated, disease-fighting state. This parameter change in microglial activation status enables them to perform their clearing function effectively, directly addressing the pathological accumulation of β-amyloid and tau that existing therapies fail to resolve.
2Ease of manufacture
If glial cell interactions are not targeted, then current treatment approaches are simple, but the underlying pathological processes of Alzheimer's disease remain unaddressed
Solution Approach 1:
By introducing IL-3 as a measurable and targetable intermediary molecule, the patent creates a specific therapeutic target that bridges the gap between treatment simplicity and effectiveness. The IL-3 signaling pathway provides a concrete molecular target that can be addressed with relatively simple therapeutic interventions while effectively clearing disease pathology.
3Stability of the object's composition
If microglia are not reprogrammed through IL-3 signaling, then the glial cell ecosystem remains in its natural state, but microglia cannot effectively cluster and clear β-amyloid and tau aggregates
Solution Approach 1:
The patent applies parameter changes to transform microglia from a resting state to an activated state through IL-3 signaling. This parameter change in microglial activation enables them to dynamically respond to and clear β-amyloid and tau aggregates, resolving the contradiction between maintaining natural glial stability and achieving effective pathology clearance.
Solution Approach 2:
The patent converts the harmful accumulation of β-amyloid and tau aggregates into a beneficial clearing process by using IL-3 signaling to activate microglia. The pathological aggregates that cause harm become the target of microglial clearance activity, transforming the harmful situation into a beneficial therapeutic outcome.
Data Source
AI summary
Described herein are compositions and methods targeting IL-3 signaling for reducing Alzheimer's disease (AD)-related pathology.